June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Choroidal thickness change following intravitreal bevacizumab therapy for wet age-related macular degeneration: Six months results
Author Affiliations & Notes
  • Sharif El Emam
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Giulio Barteselli
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Jay Chhablani
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Su-Na Lee
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Igor Kozak
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Lingyun Cheng
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • William Freeman
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Footnotes
    Commercial Relationships Sharif El Emam, None; Giulio Barteselli, None; Jay Chhablani, None; Su-Na Lee, None; Igor Kozak, None; Lingyun Cheng, Spinnaker Biosciences (C); William Freeman, OD-OS, Inc. (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4096. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sharif El Emam, Giulio Barteselli, Jay Chhablani, Su-Na Lee, Igor Kozak, Lingyun Cheng, William Freeman; Choroidal thickness change following intravitreal bevacizumab therapy for wet age-related macular degeneration: Six months results. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4096. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the change in choroidal thickness (CT) after intravitreal injections of bevacizumab (ivB) for wet age-related macular degeneration (AMD), using the enhanced depth imaging modality of spectral-domain optical coherence tomography (EDI-OCT).

Methods: This retrospective observational case series included 127 consecutive eyes of 127 patients with wet AMD, who received ivB injections. Exclusion criteria included posterior segment surgeries, and photodynamic therapy. Complete ophthalmic examination, fluorescein angiography, and EDI-OCT were performed at baseline, and during the follow-up visits. All eyes were given at least 2 ivB injections. In 35 eyes, 6 consecutive ivB were received. Manual choroidal segmentation, and subfoveal CT, mean CT in central 1000 and central 5000 microns were recorded. Differences between the baseline and post-ivB CT measurements were analyzed.

Results: The mean pre-injection CT was 171.7 μm within the central 1000 μm. A significant reduction (P < 0.005) in the CT was seen after 2 ivB in the fovea (6.3 μm), central 1000 μm (5.7 μm), and 5000 μm (4.6 μm). The reduction in the treatment naïve eyes was higher than in the previously treated ones (7.8 μm and 4.07 μm respectively). Following 6 ivB injections, significant reduction (P < 0.05) was seen in the fovea and central 1000 μm at both the 2 and 6 months visit. No significant change in CT was observed between the 2 and 6 months visit.

Conclusions: Choroidal thickness showed a diffuse significant reduction following intravitreal bevacizumab injection, which was more during the first 2 months of treatment.

Keywords: 452 choroid • 412 age-related macular degeneration • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×